17:52 , Aug 10, 2017 |  BC Innovations  |  Emerging Company Profile

Flexing against suppression

FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds,...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an unbiased...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Cancer Research U.K. deal

On Dec. 20, 2013, Cancer Research U.K.'s Drug Development Office ( DDO) and commercial subsidiary, Cancer Research Technology (CRT) Ltd., agreed to a clinical development partnership with AstraZeneca to develop the pharma's AZD2098 for...